Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab and docetaxel neoadjuvant therapy in HER2-positive breast cancer
CTR20150679Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in breast cancer, sponsored by Roche. Started Feb 2016; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20150679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150679.